Effect of increasing zanamivir in the presence of 50 µL of Capmul MCM L8 on zanamivir absolute bioavailability after intraduodenal administration in rats.

Drug resistance of MDA-MB-453.

Jatin Mehta (703766)
Shailendra Asthana (631880)
Chandi Charan Mandal (161724)
Sunita Saxena (56202)

March 2015

(A-C) MDA-MB-453 cells were treated with the indicated concentration of anti-cancer drugs paclita...

B02 increases sensitivity of MDA-MB-231 cells to DNA damaging agents.

Fei Huang (9205)
Alexander V. Mazin (255463)

June 2014

A. The structures of B02, doxorubicin, etoposide, topotecan and cisplatin. B. Survival of MDA-MB-...

Treatment with chebulanin ameliorated the clinical severity of CIA.

Yinglan Zhao (515811)
Fang Liu (13271)
Yao Liu (173014)
Dan Zhou (29408)
Qing Dai (552194)
Songqing Liu (5665216)

September 2015

CIA was induced, and after the onset of arthritis animals were treated with vehicle (control) or ...

Effect of increasing Capmul MCM L8 on the absolute bioavailability of 1.5 mg of zanamivir after intraduodenal administration in rats.

Eric H. Holmes (403612)
Harikrishna Devalapally (403613)
Libin Li (403614)
Michael L. Perdue (403615)
Gary K. Ostrander (403616)

April 2013

Zanamivir had significantly higher (p<0.01) absolute bioavailability when dosed in the Capmul MCM...

Absolute bioavailability of zanamivir after intraduodenal administration of 1.5 mg of zanamivir in 50 µL of the indicated test vehicle in rats.

Eric H. Holmes (403612)
Harikrishna Devalapally (403613)
Libin Li (403614)
Michael L. Perdue (403615)
Gary K. Ostrander (403616)

April 2013

As indicated, in some experiments the test vehicles glycerol and Capmul MCM L8 were administered ...

Timecourse of changes in plasma zanamivir concentrations with differing intraduodenally administered formulations versus intravenous administration of zanamivir in PBS.

Eric H. Holmes (403612)
Harikrishna Devalapally (403613)
Libin Li (403614)
Michael L. Perdue (403615)
Gary K. Ostrander (403616)

April 2013

A rapid uptake from the intraduodenally administered Capmul MCM L8 formulation was observed which...

Comparative pharmacokinetics of formulations after 16 days of administration.

Beth Buchanan (5007821)
Qingfang Meng (5007824)
Mathieu-Marc Poulin (5007830)
Jonathan Zuccolo (252930)
Chike Godwin Azike (5007818)
Joseph Gabriele (5007827)
David Charles Baranowski (5007815)

March 2018

Male Sprague-Dawley rats (N = 4/group) received once daily for 16 days administration of 90 mg/kg...

Comparative acute pharmacokinetics of formulations.

Beth Buchanan (5007821)
Qingfang Meng (5007824)
Mathieu-Marc Poulin (5007830)
Jonathan Zuccolo (252930)
Chike Godwin Azike (5007818)
Joseph Gabriele (5007827)
David Charles Baranowski (5007815)

March 2018

Male Sprague-Dawley rats received a single administration of 90 mg/kg of active via BBR oral gava...

Permeability Enhancers Dramatically Increase Zanamivir Absolute Bioavailability in Rats: Implications for an Orally Bioavailable Influenza Treatment

August 2016

We have demonstrated that simple formulations composed of the parent drug in combination with genera...

PBMC PAR levels in healthy volunteers and patients with cancer after ex vivo ABT-888 treatment.

Jiuping Ji (107729)
Robert J. Kinders (107719)
Yiping Zhang (107722)
Larry Rubinstein (342259)
Shivaani Kummar (107740)
Ralph E. Parchment (107744)
Joseph E. Tomaszewski (107747)
James H. Doroshow (107750)

February 2013

(A) Pooled PBMCs from healthy volunteers were treated ex vivo for 2 h with increasing concentrati...

Dxr is essential in and fosmidomycin resistance is due to a lack of uptake-1

Amanda C Brown (92772)
Tanya Parish (26264)

December 2011

2 μg/ml reserpine (RES), 40 μg/ml verapamil (VER) and 1.25 μg/ml carbonyl cyanide -chlorophenylhydra...

Clinical chemistry of liver and kidney function in chronically administered animals.

Beth Buchanan (5007821)
Qingfang Meng (5007824)
Mathieu-Marc Poulin (5007830)
Jonathan Zuccolo (252930)
Chike Godwin Azike (5007818)
Joseph Gabriele (5007827)
David Charles Baranowski (5007815)

March 2018

Male Sprague-Dawley rats (N = 4/group) received once daily for 14 days administration of 90 mg/kg...

Zanamivir Oral Delivery: Enhanced Plasma and Lung Bioavailability in Rats

��

March 2013

The objective of this study was to enhance the oral bioavailability (BA) of zanamivir (ZMR) by incre...

Carcinogenic survival assay results charting survival of PBRM1 / BAF180 knock-out cell lines with concentration intervals of the PARP inhibitor Olaparib, the POLA inhibitor Erocalciferol and the ABL inhibitor Dasatanib.

Graeme Benstead-Hume (3566114)
Xiangrong Chen (697789)
Suzanna R. Hopkins (6597443)
Karen A. Lane (6597446)
Jessica A. Downs (332831)
Frances M. G. Pearl (6597449)

April 2019

These results suggest PBRM1 mutant cells may be more sensitive to both the PARP and ABL1 inhibitors ...

Bacterial load (in terms of Log CFU/ml) in A) Hindpaws of diabetic BALB/c mice following treatment with phage MR-10, linezolid and combination of phageMR-10 and linezolid (25

Sanjay Chhibber (283732)
Tarsem Kaur (283733)
Sandeep Kaur (283735)

February 2013

mg/kg/per oral) and Phage titers(in terms of Log PFU/ml) in B) Hindpaws of phage treated (gro...

Drug resistance of MDA-MB-453.

Jatin Mehta (703766)
Shailendra Asthana (631880)
Chandi Charan Mandal (161724)
Sunita Saxena (56202)

March 2015

(A-C) MDA-MB-453 cells were treated with the indicated concentration of anti-cancer drugs paclita...

B02 increases sensitivity of MDA-MB-231 cells to DNA damaging agents.

Fei Huang (9205)
Alexander V. Mazin (255463)

June 2014

A. The structures of B02, doxorubicin, etoposide, topotecan and cisplatin. B. Survival of MDA-MB-...

Treatment with chebulanin ameliorated the clinical severity of CIA.

Yinglan Zhao (515811)
Fang Liu (13271)
Yao Liu (173014)
Dan Zhou (29408)
Qing Dai (552194)
Songqing Liu (5665216)

September 2015

CIA was induced, and after the onset of arthritis animals were treated with vehicle (control) or ...

Effect of increasing Capmul MCM L8 on the absolute bioavailability of 1.5 mg of zanamivir after intraduodenal administration in rats.

Eric H. Holmes (403612)
Harikrishna Devalapally (403613)
Libin Li (403614)
Michael L. Perdue (403615)
Gary K. Ostrander (403616)

April 2013

Zanamivir had significantly higher (p<0.01) absolute bioavailability when dosed in the Capmul MCM...

Absolute bioavailability of zanamivir after intraduodenal administration of 1.5 mg of zanamivir in 50 µL of the indicated test vehicle in rats.

Eric H. Holmes (403612)
Harikrishna Devalapally (403613)
Libin Li (403614)
Michael L. Perdue (403615)
Gary K. Ostrander (403616)

April 2013

As indicated, in some experiments the test vehicles glycerol and Capmul MCM L8 were administered ...

Timecourse of changes in plasma zanamivir concentrations with differing intraduodenally administered formulations versus intravenous administration of zanamivir in PBS.

Eric H. Holmes (403612)
Harikrishna Devalapally (403613)
Libin Li (403614)
Michael L. Perdue (403615)
Gary K. Ostrander (403616)

April 2013

A rapid uptake from the intraduodenally administered Capmul MCM L8 formulation was observed which...

Comparative pharmacokinetics of formulations after 16 days of administration.

Beth Buchanan (5007821)
Qingfang Meng (5007824)
Mathieu-Marc Poulin (5007830)
Jonathan Zuccolo (252930)
Chike Godwin Azike (5007818)
Joseph Gabriele (5007827)
David Charles Baranowski (5007815)

March 2018

Male Sprague-Dawley rats (N = 4/group) received once daily for 16 days administration of 90 mg/kg...

Comparative acute pharmacokinetics of formulations.

Beth Buchanan (5007821)
Qingfang Meng (5007824)
Mathieu-Marc Poulin (5007830)
Jonathan Zuccolo (252930)
Chike Godwin Azike (5007818)
Joseph Gabriele (5007827)
David Charles Baranowski (5007815)

March 2018

Male Sprague-Dawley rats received a single administration of 90 mg/kg of active via BBR oral gava...

Permeability Enhancers Dramatically Increase Zanamivir Absolute Bioavailability in Rats: Implications for an Orally Bioavailable Influenza Treatment

August 2016

We have demonstrated that simple formulations composed of the parent drug in combination with genera...

PBMC PAR levels in healthy volunteers and patients with cancer after ex vivo ABT-888 treatment.

Jiuping Ji (107729)
Robert J. Kinders (107719)
Yiping Zhang (107722)
Larry Rubinstein (342259)
Shivaani Kummar (107740)
Ralph E. Parchment (107744)
Joseph E. Tomaszewski (107747)
James H. Doroshow (107750)

February 2013

(A) Pooled PBMCs from healthy volunteers were treated ex vivo for 2 h with increasing concentrati...

Dxr is essential in and fosmidomycin resistance is due to a lack of uptake-1

Amanda C Brown (92772)
Tanya Parish (26264)

December 2011

2 μg/ml reserpine (RES), 40 μg/ml verapamil (VER) and 1.25 μg/ml carbonyl cyanide -chlorophenylhydra...

Clinical chemistry of liver and kidney function in chronically administered animals.

Beth Buchanan (5007821)
Qingfang Meng (5007824)
Mathieu-Marc Poulin (5007830)
Jonathan Zuccolo (252930)
Chike Godwin Azike (5007818)
Joseph Gabriele (5007827)
David Charles Baranowski (5007815)

March 2018

Male Sprague-Dawley rats (N = 4/group) received once daily for 14 days administration of 90 mg/kg...

Zanamivir Oral Delivery: Enhanced Plasma and Lung Bioavailability in Rats

��

March 2013

The objective of this study was to enhance the oral bioavailability (BA) of zanamivir (ZMR) by incre...

Carcinogenic survival assay results charting survival of PBRM1 / BAF180 knock-out cell lines with concentration intervals of the PARP inhibitor Olaparib, the POLA inhibitor Erocalciferol and the ABL inhibitor Dasatanib.

Graeme Benstead-Hume (3566114)
Xiangrong Chen (697789)
Suzanna R. Hopkins (6597443)
Karen A. Lane (6597446)
Jessica A. Downs (332831)
Frances M. G. Pearl (6597449)

April 2019

These results suggest PBRM1 mutant cells may be more sensitive to both the PARP and ABL1 inhibitors ...

Bacterial load (in terms of Log CFU/ml) in A) Hindpaws of diabetic BALB/c mice following treatment with phage MR-10, linezolid and combination of phageMR-10 and linezolid (25

Sanjay Chhibber (283732)
Tarsem Kaur (283733)
Sandeep Kaur (283735)

February 2013

mg/kg/per oral) and Phage titers(in terms of Log PFU/ml) in B) Hindpaws of phage treated (gro...

Drug resistance of MDA-MB-453.

Jatin Mehta (703766)
Shailendra Asthana (631880)
Chandi Charan Mandal (161724)
Sunita Saxena (56202)

March 2015

(A-C) MDA-MB-453 cells were treated with the indicated concentration of anti-cancer drugs paclita...

B02 increases sensitivity of MDA-MB-231 cells to DNA damaging agents.

Fei Huang (9205)
Alexander V. Mazin (255463)

June 2014

A. The structures of B02, doxorubicin, etoposide, topotecan and cisplatin. B. Survival of MDA-MB-...

Treatment with chebulanin ameliorated the clinical severity of CIA.

Yinglan Zhao (515811)
Fang Liu (13271)
Yao Liu (173014)
Dan Zhou (29408)
Qing Dai (552194)
Songqing Liu (5665216)

September 2015

CIA was induced, and after the onset of arthritis animals were treated with vehicle (control) or ...

Effect of increasing zanamivir in the presence of 50 µL of Capmul MCM L8 on zanamivir absolute bioavailability after intraduodenal administration in rats.

Abstract

Extracted data

Effect of increasing zanamivir in the presence of 50 µL of Capmul MCM L8 on zanamivir absolute bioavailability after intraduodenal administration in rats.

Abstract

Extracted data

Related items

Related items